Phase 3 survodutide trial reports greater weight loss than placebo

What happened

A phase 3 trial has reported 76-week results for survodutide, an experimental medicine that activates both glucagon and GLP-1 receptors. SYNCHRONIZE-1 enrolled 725 adults with obesity, or overweight plus at least one related health condition, who did not have diabetes.

Participants were randomly assigned to weekly injections titrated to 3.6 mg of survodutide, 6.0 mg of survodutide or placebo. Everyone also received counseling on lifestyle changes. The main analysis counted the effects of stopping treatment early, using another obesity medicine prohibited by the protocol and extending dose escalation.

In that treatment-regimen analysis, average weight changed by 12.2% below baseline in the 3.6 mg group, 13.0% below baseline in the 6.0 mg group and 5.4% below baseline with placebo at week 76. At least 5% weight loss was reached by 72.6%, 71.9% and 46.3% of participants, respectively.

Gastrointestinal symptoms were the most common adverse events and were usually mild or moderate. They occurred in 80.9% of participants assigned to 3.6 mg, 89.7% assigned to 6.0 mg and 47.9% assigned to placebo. The study reported no deaths. Boehringer Ingelheim funded the trial.

What it means

SYNCHRONIZE-1 provides randomized phase 3 evidence for weight reduction in the population studied. Both survodutide groups had larger average losses than placebo, even in an analysis designed to reflect events such as early discontinuation.

The published results also show why the average weight figure should not stand alone. Gastrointestinal problems affected most participants receiving survodutide, and the higher dose did not produce a clearly higher percentage of people reaching the 5% threshold in this analysis. Efficacy, tolerability and the ability to stay on treatment all matter.

What it does not mean

Survodutide remains investigational. A successful phase 3 trial is not an FDA approval, and products sold outside authorized research have not been reviewed as survodutide medicines. The study did not compare survodutide directly with semaglutide, tirzepatide, bariatric surgery or another active obesity treatment.

The trial excluded people with diabetes, so its results should not be transferred automatically to that group. Seventy-six weeks also cannot establish outcomes after several years or show whether treatment prevents heart attacks, strokes or death.